Gaelic Laboratories

Gaelic Laboratories

Dublin, Ireland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Gaelic Laboratories is a newly established but strategically positioned CDMO focusing exclusively on the niche Beta-Lactam antibiotic sector. Leveraging a pre-existing, HPRA-licensed facility in Ireland with a 40-year manufacturing history, the company provides end-to-end services from API handling to finished product packaging and full regulatory support. Its dual strategy involves contract manufacturing for third parties and the future commercialisation of its own generic Gaelic Laboratories-branded products, targeting growth in Europe and the emerging MENA markets.

Infectious Disease

Technology Platform

Dedicated, HPRA-licensed manufacturing and analytical infrastructure for Beta-Lactam antibiotics, offering integrated services from method development to regulatory batch release.

Opportunities

The consistent global demand for generic antibiotics and the stringent need for dedicated Beta-Lactam manufacturing facilities create a steady market.
Expansion into the growing MENA region, facilitated by its EU regulatory credentials and UAE commercial arm, presents a significant geographic growth opportunity.

Risk Factors

High concentration risk in a single drug class (Beta-Lactams) and dependence on a single facility.
Intense competition in the generics and CDMO space, coupled with the challenges of commercial execution in diverse international markets, particularly the MENA region.

Competitive Landscape

Gaelic Laboratories competes with large, diversified CDMOs (e.g., Lonza, Catalent) and established generic pharmaceutical manufacturers with in-house Beta-Lactam capacity. Its niche specialization and EU-licensed site are differentiators, but it faces competition on cost, scale, and global reach from larger players and regional manufacturers in target markets.